Literature DB >> 21561770

High affinity sialoside ligands of myelin associated glycoprotein.

Ying Zeng1, Christoph Rademacher, Corwin M Nycholat, Satoshi Futakawa, Katrin Lemme, Beat Ernst, James C Paulson.   

Abstract

Myelin associated glycoprotein (Siglec-4) is a myelin adhesion receptor, that is, well established for its role as an inhibitor of axonal outgrowth in nerve injury, mediated by binding to sialic acid containing ligands on the axonal membrane. Because disruption of myelin-ligand interactions promotes axon outgrowth, we have sought to develop potent ligand based inhibitors using natural ligands as scaffolds. Although natural ligands of MAG are glycolipids terminating in the sequence NeuAcα2-3Galβ1-3(±NeuAcα2-6)GalNAcβ-R, we previously established that synthetic O-linked glycoprotein glycans with the same sequence α-linked to Thr exhibited ∼1000-fold increased affinity (∼1μM). Attempts to increase potency by introducing a benzoylamide substituent at C-9 of the α2-3 sialic acid afforded only a two-fold increase, instead of increases of >100-fold observed for other sialoside ligands of MAG. Surprisingly, however, introduction of a 9-N-fluoro-benzoyl substituent on the α2-6 sialic acid increased affinity 80-fold, resulting in a potent inhibitor with a K(d) of 15nM. Docking this ligand to a model of MAG based on known crystal structures of other siglecs suggests that the Thr positions the glycan such that aryl substitution of the α2-3 sialic acid produces a steric clash with the GalNAc, while attaching an aryl substituent to the other sialic acid positions the substituent near a hydrophobic pocket that accounts to the increase in affinity.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21561770      PMCID: PMC3156379          DOI: 10.1016/j.bmcl.2011.04.068

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  35 in total

1.  Binding partners for the myelin-associated glycoprotein of N2A neuroblastoma cells.

Authors:  K Strenge; R Schauer; S Kelm
Journal:  FEBS Lett       Date:  1999-02-05       Impact factor: 4.124

Review 2.  Cell surface biology mediated by low affinity multivalent protein-glycan interactions.

Authors:  Brian E Collins; James C Paulson
Journal:  Curr Opin Chem Biol       Date:  2004-12       Impact factor: 8.822

3.  The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein.

Authors:  Karthik Venkatesh; Onanong Chivatakarn; Hakjoo Lee; Pushkar S Joshi; David B Kantor; Barbara A Newman; Rose Mage; Christoph Rader; Roman J Giger
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

4.  Functional groups of sialic acids involved in binding to siglecs (sialoadhesins) deduced from interactions with synthetic analogues.

Authors:  S Kelm; R Brossmer; R Isecke; H J Gross; K Strenge; R Schauer
Journal:  Eur J Biochem       Date:  1998-08-01

Review 5.  Siglecs and their roles in the immune system.

Authors:  Paul R Crocker; James C Paulson; Ajit Varki
Journal:  Nat Rev Immunol       Date:  2007-04       Impact factor: 53.106

6.  Potent glycan inhibitors of myelin-associated glycoprotein enhance axon outgrowth in vitro.

Authors:  Alka A Vyas; Ola Blixt; James C Paulson; Ronald L Schnaar
Journal:  J Biol Chem       Date:  2005-02-08       Impact factor: 5.157

7.  Antagonists of the myelin-associated glycoprotein: a new class of tetrasaccharide mimics.

Authors:  Daniel Schwizer; Heiko Gäthje; Soerge Kelm; Michele Porro; Oliver Schwardt; Beat Ernst
Journal:  Bioorg Med Chem       Date:  2006-03-31       Impact factor: 3.641

8.  Sialoside specificity of the siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein.

Authors:  Ola Blixt; Brian E Collins; Ingrid M van den Nieuwenhof; Paul R Crocker; James C Paulson
Journal:  J Biol Chem       Date:  2003-05-28       Impact factor: 5.157

9.  Multivalent ligand binding by serum mannose-binding protein.

Authors:  R T Lee; Y Ichikawa; T Kawasaki; K Drickamer; Y C Lee
Journal:  Arch Biochem Biophys       Date:  1992-11-15       Impact factor: 4.013

10.  Crystallographic and in silico analysis of the sialoside-binding characteristics of the Siglec sialoadhesin.

Authors:  Nathan R Zaccai; Andrew P May; Robert C Robinson; Leslie D Burtnick; Paul R Crocker; Reinhard Brossmer; Soerge Kelm; E Yvonne Jones
Journal:  J Mol Biol       Date:  2006-10-28       Impact factor: 5.469

View more
  7 in total

1.  Design and syntheses of hyaluronan oligosaccharide conjugates as inhibitors of CD44-Hyaluronan binding.

Authors:  Xiaowei Lu; Xuefei Huang
Journal:  Glycoconj J       Date:  2015-05-22       Impact factor: 2.916

2.  Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas.

Authors:  Cory D Rillahan; Matthew S Macauley; Erik Schwartz; Yuan He; Ryan McBride; Britni M Arlian; Janani Rangarajan; Valery V Fokin; James C Paulson
Journal:  Chem Sci       Date:  2014-06-01       Impact factor: 9.825

Review 3.  Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.

Authors:  Takashi Angata; Corwin M Nycholat; Matthew S Macauley
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

4.  On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7.

Authors:  Cory D Rillahan; Erik Schwartz; Christoph Rademacher; Ryan McBride; Janani Rangarajan; Valery V Fokin; James C Paulson
Journal:  ACS Chem Biol       Date:  2013-04-24       Impact factor: 5.100

Review 5.  Siglec Ligands.

Authors:  Anabel Gonzalez-Gil; Ronald L Schnaar
Journal:  Cells       Date:  2021-05-20       Impact factor: 6.600

6.  CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.

Authors:  Naoko Matsubara; Akihiro Imamura; Tatsuya Yonemizu; Chizuru Akatsu; Hongrui Yang; Akiharu Ueki; Natsuki Watanabe; Hajjaj Abdu-Allah; Nobutaka Numoto; Hiromu Takematsu; Shinobu Kitazume; Thomas F Tedder; Jamey D Marth; Nobutoshi Ito; Hiromune Ando; Hideharu Ishida; Makoto Kiso; Takeshi Tsubata
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

Review 7.  Why Is Eradicating Typhoid Fever So Challenging: Implications for Vaccine and Therapeutic Design.

Authors:  Yi-An Yang; Alexander Chong; Jeongmin Song
Journal:  Vaccines (Basel)       Date:  2018-07-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.